Skip to Content Contact Us
AMENDIS signed a commercialization agreement with Yissum

Amendis  is developing a genomic-measurement diagnostic test based on an AI learning machine for the purpose of preventing unnecessary life-threatening surgery for head-and-neck cancer patients..

 

Business Agreement Yissum

The company,  in collaboration with researchers from the Hebrew University in Jerusalem, developed a system based on a Self Learning Machine, that examines the need for surgery to remove tumors and neck lesions. The system will improve the diagnostic procedure and thus contribute greatly to the quality of life of the patients.

Head and neck cancer is the sixth most common cancer in the world and survival rates stand at 40-50% for a period of up to 5 years. Each year about 600,000 new patients are diagnosed and the numbers are constantly rising. In most cases, people aged 50 and older are diagnosed. The global market value for the diagnosis of head and neck cancer was estimated at $ 6.19 billion in 2014, and at a CAGR of 12.67% by 2020 the market value is estimated to reach $ 12.6 billion. Amndis’s derivative market for testing sales alone is estimated at $ 1.2 billion a year

 

Amndis has signed an Exclusive License Agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem.

 

Share

Back top top